Press release
Palatin Technologies' Obesity Drug Receives FDA Orphan Designation; Phase 2 Results Imminent (NYSE: PTN)
In an exciting development for the biopharma market, Palatin Technologies (NYSE: PTN)* announced that it has secured FDA orphan drug designation for PL7737, its oral melanocortin-4 receptor (MC4R) agonist, targeting obesity caused by leptin receptor deficiency. According to the company, this designation offers Palatin significant benefits, including tax credits, fee waivers, and potential seven-year market exclusivity upon approval. The company has begun toxicology studies with plans to submit an IND in Q4 2025 and expects clinical data in early 2026.
Major catalysts are approaching for Palatin. Palatin also shared that it has completed analysis of two key Phase 2 studies: the BMT-801 trial testing bremelanotide with tirzepatide for obesity, and the PL8177 trial for ulcerative colitis. Results from both are expected within days. If positive, each could be a major development for the pharma company.
PL7737, the drug that just received orphan drug designation, could revolutionize treatment for rare genetic obesity disorders. Unlike the only current FDA-approved treatment requiring daily injections, Palatin's oral formulation offers a more convenient alternative. The company is also exploring its use for hypothalamic obesity, with Phase 1 studies planned for late 2025. CEO Carl Spana called the designation "a key step in developing Palatin's MC4R receptor agonists for rare obesity conditions." The obesity therapeutics market is reportedly projected to reach $44 billion by 2030.
MC4R agonists represent a promising new class of therapeutics that may enhance existing GLP-1 treatments. Palatin's development of both injectable and oral MC4R agonists positions it to address multiple segments of the obesity market. Reportedly, A Pharma Analyst on Wall Street seems to be optimistic about Palatin's prospects, giving the company a Buy rating with a $7.00 price target, representing a significant premium over current levels.
[https://newsletter.page/wallstreetalerts]
Recent Palatin Technologies News Highlights:
* [https://finance.yahoo.com/news/palatin-completes-phase-2-obesity-123000283.html]
* [https://finance.yahoo.com/news/palatin-announces-positive-phase-iib-123000769.html]
* [https://finance.yahoo.com/news/palatin-announces-completion-patient-enrollment-123000466.html]
*DISCLAIMER: This alert is published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This alert contains and is a form of paid promotional content for to Palatin Technologies and was produced as part of their paid subscription to Wall Street Wire's distribution and promotional content services. This alert has not been reviewed or approved by Palatin Technologies prior to publication. Please review the full disclaimers and compensation disclosures here: https://redditwire.com/terms
Media Contact
Company Name: Wall Street Wire
Contact Person: Market Alerts Desk
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=palatin-technologies-obesity-drug-receives-fda-orphan-designation-phase-2-results-imminent-nyse-ptn]
Country: Germany
Website: https://newsletter.page/wallstreetalerts
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Palatin Technologies' Obesity Drug Receives FDA Orphan Designation; Phase 2 Results Imminent (NYSE: PTN) here
News-ID: 3943060 • Views: …
More Releases from ABNewswire
HSNCodeFinder AI Launches Global AI Platform to Simplify Product Classification …
HSNCodeFinder AI, an innovative SaaS platform, has launched globally to simplify product classification and international trade compliance. This AI-powered HSN Code Finder helps businesses accurately find the correct HSN code for any product in seconds. By automating HSN code search for multiple countries, HSNCodeFinder AI reduces manual errors and ensures smooth customs and tax operations worldwide.
October 22, 2025 - HSNCodeFinder AI today announced the launch of its advanced SaaS platform,…
Charting the Intelligence Economy: 4 Companies Transforming Market Data (ATHR, T …
In the modern market, information doesn't just guide trades; it is the trade. The distance between reading and reacting has collapsed to milliseconds, and in that blur, data itself has become the most valuable asset on the screen. Artificial intelligence is turning every article, comment, and market signal into a feedback loop of prediction. The result is a new financial ecosystem where algorithms study investors as closely as investors study…
Security Matters PLC (NASDAQ: SMX): Turning Waste Into Proof
For decades, the world has struggled to turn sustainability promises into measurable results. Recycling programs fell short, industrial polymers went untracked, and plastics remained a liability rather than an asset. Governments set targets, and companies pledged billions, yet the frameworks were never built to succeed. The outcome was predictable: recycling rates stalled, incineration rose, and the promise of a circular economy remained aspirational. That is where SMX (Security Matters, NASDAQ:SMX)…
Premier Personal Injury Law Firm McKay Law Expands to Tyler with New Downtown Of …
The new Tyler location represents McKay Law's commitment to providing accessible, sophisticated legal representation to victims of devastating accidents throughout Smith County and the surrounding East Texas region. With a proven track record of hundreds of satisfied clients and over 340 positive Google reviews, McKay Law now offers three convenient locations to serve Texas families facing life-altering injuries.
TYLER, TX - October 22, 2025 - McKay Law, a premier personal injury…
More Releases for Palatin
Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), Del …
The Key Moderate Dry Eye Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Moderate Dry Eye market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Moderate Dry Eye pipeline products will significantly revolutionize the Moderate Dry Eye market dynamics.
DelveInsight's "Moderate Dry Eye Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding…
Mild Dry Eye Market Growth Projections 2023-2032: DelveInsight Analysis | Palati …
The Key Mild Dry Eye Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Mild Dry Eye market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mild Dry Eye pipeline products will significantly revolutionize the Mild Dry Eye market dynamics.
DelveInsight's "Mild Dry Eye Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding…
Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Pal …
The Key Dry Eye Disease Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Dry Eye Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding…
Dry Eye Disease Market to Expand Significantly by 2034, States DelveInsight Repo …
The Dry Eye Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye…
Dry Eye Disease Market to Show Incremental Growth, asserts DelveInsight | Promin …
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Dry Eye Disease market report provides current treatment practices, emerging drugs, Dry Eye Disease market share of the individual therapies, current and forecasted…
Dry Eye Disease Market to Show Incremental Growth During the Study Period | Majo …
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Dry Eye Disease market report provides current treatment practices, emerging drugs, Dry Eye Disease market share of the individual therapies, current and forecasted…
